CJC-1295 DAC

The downside is where the DAC form earns its caution rating, and it centers on one feature: you cannot take it back. The sustained 6 to 8 day action means any side effect, water retention, lethargy, a reaction, persists for days. Layered on top are a heavier metabolic and fluid side-effect profile, an FDA-flagged immunogenicity risk from the albumin-binding chemistry, and an unresolved trial death in a cardiovascular-compromised patient. The form's one downside advantage is convenience: once-weekly dosing is far less effort than the daily no-DAC schedule.

Safety Risk (3.3/5.0): Safety is the dominant concern and scores notably worse than the no-DAC form. There is no established intrinsic catastrophic signal, so the score sits below the catastrophic floor, but several factors stack: an unresolved trial death roughly two hours after a dose in a patient with pre-existing coronary disease, never independently adjudicated; a sustained elevation that cannot be reversed if cardiovascular or metabolic stress appears; theoretical IGF-1-driven proliferation risk that is larger with continuous than pulsatile exposure, the same marker raised in Teichman 2006; and an FDA-flagged immunogenicity concern unique to the albumin-binding chemistry. Active cancer is an absolute contraindication.

Side Effect Profile (3.2/5.0): Side effects are heavier and longer-lasting than with no-DAC. Water retention, facial puffiness, flushing, lethargy, and headache are common, and because the form stays active for days, they do not pass in hours the way they do with the pulsatile version. Reduced insulin sensitivity is reported more often with the sustained profile. The inability to dose down quickly turns an ordinary side effect into a multi-day problem.

Financial Cost (2.5/5.0): Cost is moderate. Research-grade material is inexpensive per vial, and once-weekly dosing uses less peptide than the daily no-DAC schedule, so the recurring spend can be lower. As with all of these, the relevant framing is ongoing money spent on an unproven compound.

Time/Effort Burden (2.3/5.0): Effort is the DAC form's genuine advantage. A single weekly subcutaneous injection is far less daily logistics than the no-DAC schedule of two or three fasted injections a day. Reconstitution and cold-chain storage still apply, but the convenience of weekly dosing is real and is the main reason anyone chooses this form.

Opportunity Cost (3.0/5.0): Opportunity cost is genuine because better options exist for the same goal. Tesamorelin is FDA-approved with human fat-loss data and shares the safer pulsatile kinetics, per Falutz 2007, and the no-DAC form gives a more physiological pulse with fast reversibility. Money and effort spent on the DAC form could go to either, or to the training, protein, and sleep basics that move the same goals with far more certainty.

Dependency/Withdrawal (2.7/5.0): Dependency risk is low in the addiction sense, but the sustained stimulation raises the desensitization question more than pulsatile dosing does. CJC-1295 is non-suppressive, so there is no withdrawal syndrome, and benefits simply fade when dosing stops. The open concern is blunted response over a long continuous cycle, which is why even DAC users cycle off.

Reversibility (3.2/5.0): Reversibility is the DAC form's defining weakness and the sharpest contrast with no-DAC. A side effect or reaction triggered today persists until the drug clears, 6 to 8 days later, with no way to dose down in between. The FDA-flagged immunogenicity adds a second, potentially slower-to-resolve concern. Where the no-DAC form clears in hours, the DAC form locks you in for a week, which is the single biggest reason to prefer the short-acting version.